Versavo is a biosimilar bevacizumab and is indicated for the treatment of multiple cancers. It is used in combination with other chemotherapy drugs to treat cervical, colorectal, glioblastoma and non-squamous non-small cell lung cancer.
2-8 degrees Celsius (refrigerate),Do not freeze.
Vial containing concentrate for solution for infusion.
Intravenous (IV) (upon prescription only and administered by a healthcare provider.)
Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.